Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis

Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis

Resource Type

CF Research News

Authors

Monica Gelzo, Paola Iacotucci, Mafalda Caputo, Gustavo Cernera, Marika Comegna, Vincenzo Carnovale, Gaetano Corso,, Giuseppe Castaldoa

References

J Cyst Fibros. 2020 Jun 22;S1569-1993(20)30779-7. doi: 10.1016/j.jcf.2020.06.015. Online ahead of print

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

Cholesterol homeostasis [3]
Gas chromatography [4]
Lumacaftor/ivacaftor [5]
pancreatic insufficiency [6]

Date

Monday, June 22, 2020

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [7]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/lumacaftorivacaftor-improves-liver-cholesterol-metabolism-does-not

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-19-00503R4_FINAL_Corso_040920.pdf [2] https://pubmed.ncbi.nlm.nih.gov/32586737/ [3] https://www.ecfs.eu/research-article-keywords/cholesterol-homeostasis [4] https://www.ecfs.eu/research-article-keywords/gas-chromatography [5] https://www.ecfs.eu/research-article-keywords/lumacaftorivacaftor [6] https://www.ecfs.eu/research-article-keywords/pancreatic-insufficiency [7] https://www.ecfs.eu/resource-guideline-type/other-guidelines